IUPAC Name: 4-Amino-N-(2-diethylaminoethyl)benzamide  
Synonyms: 4-Aminobenzoic acid 2-diethylaminoethylamide ; 4-Amino-N-[2-(diethylamino)ethyl]benzamid ; 4-Amino-N-[2-(diethylamino)ethyl]benzamide ; 4-Amino-N-[2-(diéthylamino)éthyl]benzamide ; Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-
CAS NO:51-06-9
Molecular Formula of p-Amino-n-(2-diethylaminoethyl)-benzamide (CAS NO.51-06-9) :C₁₃H₂₁N₃O
Molecular Weight of p-Amino-n-(2-diethylaminoethyl)-benzamide (CAS NO.51-06-9) :235.3253
Molecular Structure of p-Amino-n-(2-diethylaminoethyl)-benzamide (CAS NO.51-06-9) :
Index of Refraction: 1.553
Surface Tension: 43.8 dyne/cm 
Density: 1.06 g/cm³ 
Flash Point: 208.9 °C 
Enthalpy of Vaporization: 67.58 kJ/mol 
Boiling Point: 421.8 °C at 760 mmHg 
Vapour Pressure: 2.54E-07 mmHg at 25°C 

It was introduced in 1951.
Procanbid will no longer be manufactured.

 P-Amino-n-(2-diethylaminoethyl)-benzamide (CAS NO.51-06-9) is used for both supraventricular and ventricular arrhythmias. For example, it can be used to convert new-onset atrial fibrillation, though it is suboptimal for this purpose. It can also be used to treat Wolf-Parkinson-White syndrome by prolonging the refractory period of the accessory pathway. Typically use is secondary to lidocaine in patients who are allergic to lidocaine or dysrhythmias that are refractory to lidocaine.

Poison by intravenous and intraperitoneal routes. Moderately toxic by ingestion. Human systemic effects by ingestion: cardiac abnormalities, joint effects, cough, tremors, dyspnea, and other lung effects. When heated to decomposition it emits toxic fumes of NO_x.

Administration:Procainamide is administered intravenously or orally. When administered intravenously, a loading dose should first be given, though care should be taken not to cause hypotension. Procainamide's active metabolite is N-acetyl procainamide, which is stronger than procainamide and excreted by the kidneys and the renal system. Loading dose is 100mg IV bolus given slowly over 5 minutes. Max dose is 17mg/kg. Use is discontinued when dysrhythmia is suppressed, or if hypotension ensues, QRS complex widens by 50% or more, or maximum dose is achieved.
Side effects:Adverse effects include rash, myalgia, hypersensitivity reactions (fever, agranulocytosis), Drug-Induced Lupus Erythematosus (particularly in slow-acetylators), and proarrhythmic effects (e.g., torsades de pointes). Treatment with procainamide can cause antibody production against cellular components, accounting for the systemic lupus erythematosus-like adverse reactions